Published in Am J Psychiatry on March 01, 1995
Assessment of Valproate on Ethanol Withdrawal (PAVE) | NCT03235531
Glutamatergic substrates of drug addiction and alcoholism. Biochem Pharmacol (2007) 3.06
Binge ethanol administration enhances the MDMA-induced long-term 5-HT neurotoxicity in rat brain. Psychopharmacology (Berl) (2006) 2.12
Identifying the neural circuitry of alcohol craving and relapse vulnerability. Addict Biol (2008) 1.72
Family history of alcohol dependence and initial antidepressant response to an N-methyl-D-aspartate antagonist. Biol Psychiatry (2008) 1.71
Acamprosate produces its anti-relapse effects via calcium. Neuropsychopharmacology (2013) 1.35
kappa-Opioid receptor signaling and brain reward function. Brain Res Rev (2009) 1.32
ENT1 regulates ethanol-sensitive EAAT2 expression and function in astrocytes. Alcohol Clin Exp Res (2010) 1.19
Of mice, rats and men: Revisiting the quinolinic acid hypothesis of Huntington's disease. Prog Neurobiol (2009) 1.18
Acute ethanol impairs photic and nonphotic circadian phase resetting in the Syrian hamster. Am J Physiol Regul Integr Comp Physiol (2008) 1.07
Dexmedetomidine as adjunct treatment for severe alcohol withdrawal in the ICU. Ann Intensive Care (2012) 0.94
Ceftriaxone attenuates ethanol drinking and restores extracellular glutamate concentration through normalization of GLT-1 in nucleus accumbens of male alcohol-preferring rats. Neuropharmacology (2015) 0.93
Memantine, an NMDA receptor antagonist, differentially influences Go/No-Go performance and fMRI activity in individuals with and without a family history of alcoholism. Psychopharmacology (Berl) (2012) 0.92
Pharmacogenetic insights to monoaminergic dysfunction in alcohol dependence. Psychopharmacology (Berl) (2004) 0.90
Ethanol withdrawal-induced brain metabolites and the pharmacological effects of acamprosate in mice lacking ENT1. Neuropharmacology (2012) 0.87
Life-threatening brain failure and agitation in the intensive care unit. Crit Care (2000) 0.86
A daily process examination of the bidirectional relationship between craving and alcohol consumption as measured via interactive voice response. Alcohol Clin Exp Res (2013) 0.85
The Interplay between the Hippocampus and Amygdala in Regulating Aberrant Hippocampal Neurogenesis during Protracted Abstinence from Alcohol Dependence. Front Psychiatry (2013) 0.84
Initiating acamprosate within-detoxification versus post-detoxification in the treatment of alcohol dependence. Addict Behav (2009) 0.83
Sustained ethanol inhibition of native AMPA receptors on medial septum/diagonal band (MS/DB) neurons. Br J Pharmacol (2000) 0.83
Dopamine and N-methyl-D-aspartate receptor expression in peripheral blood of patients undergoing alcohol withdrawal. J Neural Transm (Vienna) (2007) 0.81
Polymorphisms in the NMDA subunit 2B are not associated with alcohol dependence and alcohol withdrawal-induced seizures and delirium tremens. Eur Arch Psychiatry Clin Neurosci (2004) 0.81
Role of altered structure and function of NMDA receptors in development of alcohol dependence. Curr Neuropharmacol (2005) 0.80
N-methyl-d-aspartic acid receptors are altered by stress and alcohol in Wistar-Kyoto rat brain. Neuroscience (2010) 0.80
Differential effects of ethanol on glycine uptake mediated by the recombinant GLYT1 and GLYT2 glycine transporters. Br J Pharmacol (2000) 0.79
Current approaches to the recognition and treatment of alcohol withdrawal and delirium tremens: "old wine in new bottles" or "new wine in old bottles". Prim Care Companion J Clin Psychiatry (2010) 0.79
Proteomic profiling of the phosphoproteins in the rat thalamus, hippocampus and frontal lobe after propofol anesthesia. BMC Anesthesiol (2014) 0.78
The development of acamprosate as a treatment against alcohol relapse. Expert Opin Drug Discov (2014) 0.76
Alcohol withdrawal kindling: is there a role for anticonvulsants? Psychiatry (Edgmont) (2005) 0.76
Pathophysiology of alcoholism. Am J Psychiatry (1996) 0.75
Adolescent Mice Are Resilient to Alcohol Withdrawal-Induced Anxiety and Changes in Indices of Glutamate Function within the Nucleus Accumbens. Front Cell Neurosci (2016) 0.75
Alcohol, Excitotoxicity and Adult Brain Damage: An Experimentally Unproven Chain-of-Events. Front Mol Neurosci (2016) 0.75
Pathophysiology of alcoholism. Am J Psychiatry (1996) 0.75
Pathophysiology of alcoholism. Am J Psychiatry (1996) 0.75
Successful use of oxazepam in the treatment of delirium tremens. Prim Care Companion CNS Disord (2012) 0.75
Alcohol Withdrawal Syndrome: Benzodiazepines and Beyond. J Clin Diagn Res (2015) 0.75
Six-month outcome in bipolar spectrum alcoholics treated with acamprosate after detoxification: a retrospective study. Int J Environ Res Public Health (2014) 0.75
Peter Riederer "70th birthday" neurobiological foundations of modern addiction treatment. J Neural Transm (Vienna) (2012) 0.75
Unintended changes in cognition, mood, and behavior arising from cell-based interventions for neurological conditions: ethical challenges. Am J Bioeth (2009) 6.13
Alzheimer's disease and senile dementia: loss of neurons in the basal forebrain. Science (1982) 5.63
Acute effects of cocaine on human brain activity and emotion. Neuron (1997) 4.88
Alzheimer's disease: a disorder of cortical cholinergic innervation. Science (1983) 4.40
Psychosocial treatments for cocaine dependence: National Institute on Drug Abuse Collaborative Cocaine Treatment Study. Arch Gen Psychiatry (1999) 4.22
Neurology and psychiatry: closing the great divide. Neurology (2000) 3.68
The emerging role of glutamate in the pathophysiology and treatment of schizophrenia. Am J Psychiatry (2001) 3.20
Alzheimer disease: evidence for selective loss of cholinergic neurons in the nucleus basalis. Ann Neurol (1981) 3.18
Glutamate toxicity in a neuronal cell line involves inhibition of cystine transport leading to oxidative stress. Neuron (1989) 3.06
Abnormal excitatory amino acid metabolism in amyotrophic lateral sclerosis. Ann Neurol (1990) 2.66
Oxidative stress in neurodegenerative diseases. Annu Rev Pharmacol Toxicol (1996) 2.56
A placebo-controlled trial of D-cycloserine added to conventional neuroleptics in patients with schizophrenia. Arch Gen Psychiatry (1999) 2.44
D-serine added to antipsychotics for the treatment of schizophrenia. Biol Psychiatry (1998) 2.36
Catecholamine uptake by synaptosomes from rat brain. Structure-activity relationships of drugs with differential effects on dopamine and norepinephrine neurons. Mol Pharmacol (1971) 2.08
Lesion of striatal neurones with kainic acid provides a model for Huntington's chorea. Nature (1976) 2.08
Regional differences in H3-norepinephrine and H3-dopamine uptake into rat brain homogenates. J Pharmacol Exp Ther (1969) 1.99
Targeted disruption of serine racemase affects glutamatergic neurotransmission and behavior. Mol Psychiatry (2008) 1.88
Immature cortical neurons are uniquely sensitive to glutamate toxicity by inhibition of cystine uptake. FASEB J (1990) 1.86
The Addiction Severity Index: a field study of internal consistency and validity. J Subst Abuse Treat (2000) 1.82
Antiparkinsonian drugs: inhibition of dopamine uptake in the corpus striatum as a possible mechanism of action. Science (1969) 1.81
Dopaminergic dsyfunction in Tourette syndrome. Ann Neurol (1982) 1.79
Immunocytochemical localization of N-acetyl-aspartate with monoclonal antibodies. Neuroscience (1991) 1.78
The role of glutamatergic neurotransmission in the pathophysiology of alcoholism. Annu Rev Med (1998) 1.72
Abnormal excitatory neurotransmitter metabolism in schizophrenic brains. Arch Gen Psychiatry (1995) 1.71
Modulation of N-methyl-D-aspartate receptor function by glycine transport. Proc Natl Acad Sci U S A (1998) 1.71
Prostate-specific membrane antigen is a hydrolase with substrate and pharmacologic characteristics of a neuropeptidase. Proc Natl Acad Sci U S A (1996) 1.70
Pilot studies of telemedicine for patients with obsessive-compulsive disorder. Am J Psychiatry (1995) 1.66
Hydrolysis of the brain dipeptide N-acetyl-L-aspartyl-L-glutamate. Identification and characterization of a novel N-acetylated alpha-linked acidic dipeptidase activity from rat brain. J Biol Chem (1987) 1.64
Cell-based interventions for neurologic conditions: ethical challenges for early human trials. Neurology (2008) 1.57
The National Institute on Drug Abuse Collaborative Cocaine Treatment Study. Rationale and methods. Arch Gen Psychiatry (1997) 1.56
Catecholamines in fetal and newborn rat brain. J Neurochem (1973) 1.55
Cocaine dependence with and without PTSD among subjects in the National Institute on Drug Abuse Collaborative Cocaine Treatment Study. Am J Psychiatry (1998) 1.49
Tyrosine hydroxylase in rat brain--cofactor requirements, regional and subcellular distribution. Biochem Pharmacol (1972) 1.49
N-acetylaspartate in neuropsychiatric disorders. Prog Neurobiol (1995) 1.47
Catecholamine uptake by synaptosomes in homogenates of rat brain: stereospecificity in different areas. J Pharmacol Exp Ther (1969) 1.43
Hydroxychloroquine retinopathy. Ophthalmology (2001) 1.42
Nitric oxide-induced motor neuron disease in a patient with alcoholism. N Engl J Med (1995) 1.41
Goldenhar's syndrome. Arch Ophthalmol (1991) 1.40
Neuroleptic malignant syndrome: life-threatening complication of neuroleptic treatment in adolescents with affective disorder. Pediatrics (1991) 1.40
Evidence for a cholinergic projection to neocortex from neurons in basal forebrain. Proc Natl Acad Sci U S A (1979) 1.27
Nicotinic acetylcholine binding sites in Alzheimer's disease. Brain Res (1986) 1.26
Predictors of self-help group attendance in cocaine dependent patients. J Stud Alcohol (2000) 1.25
Serine racemase deletion disrupts memory for order and alters cortical dendritic morphology. Genes Brain Behav (2010) 1.25
In situ injection of kainic acid: a new method for selectively lesioning neural cell bodies while sparing axons of passage. J Comp Neurol (1978) 1.25
Neurotoxic action of kainic acid. J Neurochem (1983) 1.24
Specific binding of [3H]kainic acid to receptor sites in rat brain. Mol Pharmacol (1979) 1.21
Histological and neurochemical effects of fetal treatment with methylazoxymethanol on rat neocortex in adulthood. Brain Res (1979) 1.21
Keratoconus and eye rubbing. Am J Ophthalmol (1984) 1.20
The regional vulnerability to hypoglycemia-induced neurotoxicity in organotypic hippocampal culture: protection by early tetrodotoxin or delayed MK-801. J Neurosci (1992) 1.19
Increased glutamatergic neurotransmission and oxidative stress after alcohol withdrawal. Am J Psychiatry (1998) 1.19
The role of brain dopamine in behavioral regulation and the actions of psychotropic drugs. Am J Psychiatry (1970) 1.18
Cortical degeneration with swollen chromatolytic neurons: its relationship to Pick's disease. J Neuropathol Exp Neurol (1986) 1.15
Kainic acid stimulates excitatory amino acid neurotransmitter release at presynaptic receptors. Nature (1982) 1.15
Gender differences in cocaine craving among non-treatment-seeking individuals with cocaine dependence. Am J Drug Alcohol Abuse (2001) 1.15
Psychotropic drug use in very young children. JAMA (2000) 1.15
Platelet serotonin, a possible marker for familial autism. J Autism Dev Disord (1991) 1.14
Dose-finding trial of D-cycloserine added to neuroleptics for negative symptoms in schizophrenia. Am J Psychiatry (1995) 1.13
Primary degenerative dementia without Alzheimer pathology. Can J Neurol Sci (1986) 1.13
Association of postoperative delirium with raised serum levels of anticholinergic drugs. Lancet (1981) 1.13
Glutamate neurotoxicity and the inhibition of protein synthesis in the hippocampal slice. J Neurochem (1991) 1.11
N-acetyl-aspartyl-glutamate: regional levels in rat brain and the effects of brain lesions as determined by a new HPLC method. J Neurochem (1984) 1.10
Immunocytochemical localization of the N-acetyl-aspartyl-glutamate (NAAG) hydrolyzing enzyme N-acetylated alpha-linked acidic dipeptidase (NAALADase). J Comp Neurol (1992) 1.09
Topographic analysis of the innervation of the rat neocortex and hippocampus by the basal forebrain cholinergic system. J Comp Neurol (1983) 1.09
Selective destruction of neurons by a transmitter agonist. Science (1977) 1.08
Avoidance conditioning in different strains of rats: neurochemical correlates. Psychopharmacologia (1973) 1.08
Enhanced NAD(P)H:quinone reductase activity prevents glutamate toxicity produced by oxidative stress. J Neurochem (1991) 1.08
Antioxidants protect against glutamate-induced cytotoxicity in a neuronal cell line. J Pharmacol Exp Ther (1989) 1.07
Intracellular modulation of NMDA receptor function by antipsychotic drugs. J Neurosci (2000) 1.07
Glutamate carboxypeptidase II is expressed by astrocytes in the adult rat nervous system. J Comp Neurol (1999) 1.07
Neurochemical aspects of the ontogenesis of cholinergic neurons in the rat brain. Brain Res (1976) 1.06
Serum levels of anticholinergic drugs in treatment of acute extrapyramidal side effects. Arch Gen Psychiatry (1980) 1.06
Folylpoly-gamma-glutamate carboxypeptidase from pig jejunum. Molecular characterization and relation to glutamate carboxypeptidase II. J Biol Chem (1998) 1.06
Neurochemical aspects of the ontogenesis of GABAnergic neurons in the rat brain. Brain Res (1976) 1.05
Glutamate and related acidic excitatory neurotransmitters: from basic science to clinical application. FASEB J (1987) 1.04
Direct observation of the agonist-specific regional vulnerability to glutamate, NMDA, and kainate neurotoxicity in organotypic hippocampal cultures. Exp Neurol (1991) 1.04
The neurobiologic consequences of Down syndrome. Brain Res Bull (1986) 1.04
Neocortical cholinergic innervation: a description of extrinsic and intrinsic components in the rat. Exp Brain Res (1981) 1.04
Down syndrome, Alzheimer's disease and the trisomy 16 mouse. Trends Neurosci (1988) 1.04
The distribution and orientation of noradrenergic fibers in neocortex of the rat: an immunofluorescence study. J Comp Neurol (1978) 1.04
Dopamine receptors localised on cerebral cortical afferents to rat corpus striatum. Nature (1978) 1.03
Ontogenetic development of kainate neurotoxicity: correlates with glutamatergic innervation. Proc Natl Acad Sci U S A (1978) 1.03
N-acetylaspartylglutamate: an endogenous peptide with high affinity for a brain "glutamate" receptor. Proc Natl Acad Sci U S A (1983) 1.03
Alzheimer's disease and Down's syndrome. Ann N Y Acad Sci (1982) 1.01
Molecular characterization of human brain N-acetylated alpha-linked acidic dipeptidase (NAALADase). J Pharmacol Exp Ther (1998) 1.01
Neuronal localization of specific brain phosphoproteins. Brain Res (1978) 0.99
Self-help group attendance and participation among cocaine dependent patients. Drug Alcohol Depend (2000) 0.99
D-cycloserine added to clozapine for patients with schizophrenia. Am J Psychiatry (1996) 0.99
Heterogeneity of sodium-dependent excitatory amino acid uptake mechanisms in rat brain. J Neurosci Res (1986) 0.99
Improved cognition in Alzheimer's disease with short-term D-cycloserine treatment. Am J Psychiatry (1999) 0.98
Site-directed mutagenesis of predicted active site residues in glutamate carboxypeptidase II. Mol Pharmacol (1999) 0.98
Ontogenesis of dopaminergic-cholinergic interactions in the rat striatum: a neurochemical study. J Neurochem (1976) 0.98
Serum levels of anticholinergic drugs and impaired recent memory in chronic schizophrenic patients. Am J Psychiatry (1982) 0.98
Detection of the effects of dopamine receptor supersensitivity using pharmacological MRI and correlations with PET. Synapse (2000) 0.97
Striatal lesions with kainic acid: neurochemical characteristics. Brain Res (1977) 0.97
The immunocytochemical localization of N-acetylaspartyl glutamate, its hydrolysing enzyme NAALADase, and the NMDAR-1 receptor at a vertebrate neuromuscular junction. Neuroscience (1995) 0.97
N-Acetylaspartylglutamate: possible role as the neurotransmitter of the lateral olfactory tract. Proc Natl Acad Sci U S A (1985) 0.97
Cholinergic innervation of mouse forebrain structures. J Comp Neurol (1994) 0.97
Postcardiotomy delirium: a critical review. J Thorac Cardiovasc Surg (1979) 0.96
Rat brain N-acetylated alpha-linked acidic dipeptidase activity. Purification and immunologic characterization. J Biol Chem (1990) 0.96
Serum haloperidol levels in Gilles de la Tourette syndrome. Biol Psychiatry (1981) 0.95